

Andreas M Beyer

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1978511/publications.pdf>

Version: 2024-02-01

70
papers

2,020
citations

236925

25
h-index

254184

43
g-index

70
all docs

70
docs citations

70
times ranked

2746
citing authors

#	ARTICLE	IF	CITATIONS
1	Prolonged endothelial-dysfunction in human arterioles following infection with SARS-CoV-2. <i>Cardiovascular Research</i> , 2022, 118, 18-19.	3.8	9
2	Endothelial dysfunction as a complication of anti-cancer therapy. , 2022, 237, 108116.		14
3	Greenspace, Inflammation, Cardiovascular Health, and Cancer: A Review and Conceptual Framework for Greenspace in Cardio-Oncology Research. <i>International Journal of Environmental Research and Public Health</i> , 2022, 19, 2426.	2.6	16
4	Chemotherapy, Microvascular Function, and Angiogenesis –a Longitudinal Study. <i>FASEB Journal</i> , 2022, 36, .	0.5	0
5	Examining the role of Drp1 in age-related microvascular dysfunction. <i>FASEB Journal</i> , 2022, 36, .	0.5	0
6	Circulating Factors Provoke Endothelial Dysfunction in the Human Microcirculation Following Doxorubicin Chemotherapy. <i>FASEB Journal</i> , 2022, 36, .	0.5	0
7	Mitochondrial Telomerase Prevents Chemotherapy-induced Cardiovascular Toxicity. <i>FASEB Journal</i> , 2022, 36, .	0.5	0
8	Stratification by Race Reveals Disparate Vascular Toxicity in Response to Anti-Cancer Therapies. <i>FASEB Journal</i> , 2022, 36, .	0.5	0
9	Take charge during treatment: A planned exercise protocol to evaluate disparities and cardiovascular outcomes in Black and White patients with breast cancer undergoing treatment.. <i>Journal of Clinical Oncology</i> , 2022, 40, TPS12138-TPS12138.	1.6	0
10	Critical Interaction Between Telomerase and Autophagy in Mediating Flow-Induced Human Arteriolar Vasodilation. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2021, 41, 446-457.	2.4	14
11	Sweat the small stuff: The human microvasculature and heart disease. <i>Microcirculation</i> , 2021, 28, e12658.	1.8	4
12	Hypertension preserves the magnitude of microvascular flow-mediated dilation following transient elevation in intraluminal pressure. <i>Physiological Reports</i> , 2021, 9, e14507.	1.7	2
13	Preclinical Models of Cancer Therapy-associated Cardiovascular Toxicity: A Scientific Statement From the American Heart Association. <i>Circulation Research</i> , 2021, 129, e21-e34.	4.5	37
14	Pulling back the curtain on anthracycline cardiotoxicity: the hidden role of the microcirculation. <i>Cardiovascular Research</i> , 2021, , .	3.8	1
15	Vascular effects of disrupting endothelial mTORC1 signaling in obesity. <i>American Journal of Physiology - Regulatory Integrative and Comparative Physiology</i> , 2021, 321, R228-R237.	1.8	2
16	Dietary Sodium Restriction Results in Tissue-Specific Changes in DNA Methylation in Humans. <i>Hypertension</i> , 2021, 78, 434-446.	2.7	9
17	Autophagy, TERT, and mitochondrial dysfunction in hyperoxia. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2021, 321, H985-H1003.	3.2	11
18	Modulation of p66Shc impairs cerebrovascular myogenic tone in low renin but not low nitric oxide models of systemic hypertension. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2021, 321, H1096-H1102.	3.2	5

#	ARTICLE	IF	CITATIONS
19	Targeting muscle-enriched long non-coding RNA <i>H19</i> reverses pathological cardiac hypertrophy. <i>European Heart Journal</i> , 2020, 41, 3462-3474.	2.2	81
20	BCR-ABL tyrosine kinase inhibitors promote pathological changes in dilator phenotype in the human microvasculature. <i>Microcirculation</i> , 2020, 27, e12625.	1.8	6
21	Vascular autophagy in health and disease. <i>Basic Research in Cardiology</i> , 2020, 115, 41.	5.9	58
22	Effects of Anti-Cancer Therapy on Human Microvascular Function – a Longitudinal Study. <i>FASEB Journal</i> , 2020, 34, 1-1.	0.5	0
23	Detrimental effects of chemotherapy on human coronary microvascular function. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2019, 317, H705-H710.	3.2	31
24	Cancer therapy-induced cardiovascular toxicity: old/new problems and old drugs. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2019, 317, H164-H167.	3.2	17
25	Mitochondrial Oxidative Phosphorylation defect in the Heart of Subjects with Coronary Artery Disease. <i>Scientific Reports</i> , 2019, 9, 7623.	3.3	59
26	Telomerase Deficiency Predisposes to Heart Failure and Ischemia-Reperfusion Injury. <i>Frontiers in Cardiovascular Medicine</i> , 2019, 6, 31.	2.4	26
27	Visualization and quantification of mitochondrial structure in the endothelium of intact arteries. <i>Cardiovascular Research</i> , 2019, 115, 1546-1556.	3.8	21
28	Vascular autophagy in physiology and pathology. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2019, 316, H183-H185.	3.2	5
29	Integrative Effects of Autophagy and Telomerase on Arteriolar Flow-Mediated Dilation in Health and Coronary Artery Disease. <i>FASEB Journal</i> , 2019, 33, 684.2.	0.5	0
30	Adverse Effects of Chemotherapy on Human Microvascular Function. <i>FASEB Journal</i> , 2019, 33, lb453.	0.5	2
31	Hyperoxia Causes Mitochondrial Fragmentation in Pulmonary Endothelial Cells by Increasing Expression of Pro-Fission Proteins. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2018, 38, 622-635.	2.4	46
32	Detection of hydrogen peroxide production in the isolated rat lung using Amplex red. <i>Free Radical Research</i> , 2018, 52, 1052-1062.	3.3	11
33	Lysophosphatidic acid acts on LPA ₁ receptor to increase H ₂ O ₂ during flow-induced dilation in human adipose arterioles. <i>British Journal of Pharmacology</i> , 2018, 175, 4266-4280.	5.4	11
34	Telomerase. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2018, 38, 1247-1249.	2.4	2
35	Chemotherapeutic-Induced Cardiovascular Dysfunction: Physiological Effects, Early Detection – The Role of Telomerase to Counteract Mitochondrial Defects and Oxidative Stress. <i>International Journal of Molecular Sciences</i> , 2018, 19, 797.	4.1	14
36	Telomerase reverse transcriptase protects against angiotensin II-induced microvascular endothelial dysfunction. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2018, 314, H1053-H1060.	3.2	37

#	ARTICLE	IF	CITATIONS
37	Neoadjuvant Chemotherapy Decreases Angiogenesis Potential and Microvascular Function in Human Breast Cancer Patients. <i>FASEB Journal</i> , 2018, 32, 845.6.	0.5	0
38	LPA-induced activation of LPA 1 receptor leads to the loss of NO-mediated flow-induced dilation in human microvessels. <i>FASEB Journal</i> , 2018, 32, 713.15.	0.5	0
39	Dysbacteriosis an Inciting Cause of Endothelial Dysfunction mediated through Mitochondrial DNA Interactions. <i>FASEB Journal</i> , 2018, 32, 582.3.	0.5	0
40	5,6-DHTL, a stable metabolite of arachidonic acid, is a potential EDHF that mediates microvascular dilation. <i>Free Radical Biology and Medicine</i> , 2017, 103, 87-94.	2.9	14
41	PGC-1 β (Peroxisome Proliferator-Activated Receptor β Coactivator 1- β) Overexpression in Coronary Artery Disease Recruits NO and Hydrogen Peroxide During Flow-Mediated Dilation and Protects Against Increased Intraluminal Pressure. <i>Hypertension</i> , 2017, 70, 166-173.	2.7	41
42	Transition in the mechanism of flow-mediated dilation with aging and development of coronary artery disease. <i>Basic Research in Cardiology</i> , 2017, 112, 5.	5.9	64
43	Vascular Actions of Angiotensin $\text{1}\beta$ in the Human Microcirculation. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2016, 36, 1254-1262.	2.4	55
44	Friend or foe? Telomerase as a pharmacological target in cancer and cardiovascular disease. <i>Pharmacological Research</i> , 2016, 111, 422-433.	7.1	31
45	Mitochondrial signaling in the vascular endothelium: beyond reactive oxygen species. <i>Basic Research in Cardiology</i> , 2016, 111, 26.	5.9	39
46	Critical Role for Telomerase in the Mechanism of Flow-Mediated Dilation in the Human Microcirculation. <i>Circulation Research</i> , 2016, 118, 856-866.	4.5	88
47	The Human Microcirculation. <i>Circulation Research</i> , 2016, 118, 157-172.	4.5	222
48	Regulation of Insulin Receptor Trafficking by Bardet Biedl Syndrome Proteins. <i>PLoS Genetics</i> , 2015, 11, e1005311.	3.5	57
49	Response to "Does Angiotensin-Dependent Superoxide Production Help to Prevent Salt-Induced Endothelial Dysfunction in 2 Kidney-1 Clip Hypertensive Rats?". <i>American Journal of Hypertension</i> , 2014, 27, 640-640.	2.0	0
50	An acute rise in intraluminal pressure shifts the mediator of flow-mediated dilation from nitric oxide to hydrogen peroxide in human arterioles. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2014, 307, H1587-H1593.	3.2	54
51	Ceramide Changes the Mediator of Flow-Induced Vasodilation From Nitric Oxide to Hydrogen Peroxide in the Human Microcirculation. <i>Circulation Research</i> , 2014, 115, 525-532.	4.5	105
52	Amelioration of salt-induced vascular dysfunction in mesenteric arteries of Dahl salt-sensitive rats by missense mutation of extracellular superoxide dismutase. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2014, 306, H339-H347.	3.2	12
53	In-depth proteomic analysis of human tropomyosin by top-down mass spectrometry. <i>Journal of Muscle Research and Cell Motility</i> , 2013, 34, 199-210.	2.0	40
54	AT1 Receptors Prevent Salt-Induced Vascular Dysfunction in Isolated Middle Cerebral Arteries of 2 Kidney-1 Clip Hypertensive Rats. <i>American Journal of Hypertension</i> , 2013, 26, 1398-1404.	2.0	10

#	ARTICLE	IF	CITATIONS
55	Prolonged treatment with angiotensin 1 ^α improves endothelial function in diet-induced obesity. <i>Journal of Hypertension</i> , 2013, 31, 730-738.	0.5	35
56	Decreased Telomerase Activity Sensitizes the Resistance Vasculature to Stress-Induced Endothelial Dysfunction. <i>FASEB Journal</i> , 2013, 27, 678.1.	0.5	0
57	Inhibition of Neutral Sphingomyelinase Prevents High Pressure-Induced Shift in the Mediator of Endothelium-Dependent Dilation from NO to H ₂ O ₂ . <i>FASEB Journal</i> , 2013, 27, 901.1.	0.5	0
58	Dahl Salt-Sensitive Rats Are Protected Against Vascular Defects Related to Diet-Induced Obesity. <i>Hypertension</i> , 2012, 60, 404-410.	2.7	26
59	Regulation of the human coronary microcirculation. <i>Journal of Molecular and Cellular Cardiology</i> , 2012, 52, 814-821.	1.9	49
60	Hexosamine pathway activation and O-linked-N-acetylglucosamine ^α Novel mediators of endothelial dysfunction in hyperglycemia and diabetes. <i>Vascular Pharmacology</i> , 2012, 56, 113-114.	2.1	9
61	Decreased Telomerase Activity Converts the Mechanism of FMD from NO to H ₂ O ₂ in Human and Mouse Arterioles. <i>FASEB Journal</i> , 2012, 26, 676.1.	0.5	0
62	Inactivation of Bardet-Biedl syndrome genes causes kidney defects. <i>American Journal of Physiology - Renal Physiology</i> , 2011, 300, F574-F580.	2.7	26
63	Bioinformatic Analysis of Gene Sets Regulated by Ligand-Activated and Dominant-Negative Peroxisome Proliferator-Activated Receptor ^β in Mouse Aorta. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2010, 30, 518-525.	2.4	26
64	Contrasting vascular effects caused by loss of Bardet-Biedl syndrome genes. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2010, 299, H1902-H1907.	3.2	14
65	Interference with PPAR ^γ Function in Smooth Muscle Causes Vascular Dysfunction and Hypertension. <i>Cell Metabolism</i> , 2008, 7, 215-226.	16.2	153
66	Endothelium-Specific Interference With Peroxisome Proliferator Activated Receptor Gamma Causes Cerebral Vascular Dysfunction in Response to a High-Fat Diet. <i>Circulation Research</i> , 2008, 103, 654-661.	4.5	89
67	Interference With PPAR ^γ Signaling Causes Cerebral Vascular Dysfunction, Hypertrophy, and Remodeling. <i>Hypertension</i> , 2008, 51, 867-871.	2.7	104
68	Germ line activation of the Tie2 and SMMHC promoters causes noncell-specific deletion of floxed alleles. <i>Physiological Genomics</i> , 2008, 35, 1-4.	2.3	59
69	Vascular hypercontractility to endothelin 1 in mice lacking endothelial PPARG. <i>FASEB Journal</i> , 2008, 22, 968.12.	0.5	0
70	Gene expression profiling of potential PPAR ^γ target genes in mouse aorta. <i>Physiological Genomics</i> , 2004, 18, 33-42.	2.3	47